Poor
Not Aligned
Patient Risk:
High
Summary
Several claims about hepatic adverse effects lack support from the provided label excerpts (e.g., numeric incidence, severity/reversibility characterization, age/susceptibility rationale, LFT monitoring frequency). Most importantly, the recommended dosing claim is contradicted by the label (label: 100 mg initial then 50 mg q12h; AI: 100 mg q12h for 5-14 days).
Category Scores
Accurate Statements
Tigecycline is an antibiotic associated with liver enzyme changes in some patients.
Supported: 5.4 Hepatic Adverse Effects (increases in bilirubin/prothrombin time/transaminases).
In some cases, tigecycline-induced liver enzyme changes were severe and required discontinuation of the medication.
Partially supported: 5.4 describes significant hepatic dysfunction/hepatic failure; 6.1 indicates discontinuation due to adverse reactions.
The use of other medications that affect liver function (e.g., acetaminophen or statins) may increase the risk of tigecycline-induced liver enzyme changes.
Partially supported: 5.4 notes some patients received multiple concomitant medications; provided examples (acetaminophen/statins) not specifically supported in provided excerpts.
Healthcare providers should consider patients with a history of liver disease, renal impairment, or other conditions that may affect liver function to be closely monitored for tigecycline-induced liver enzyme changes.
Partially supported: 5.4 supports monitoring/evaluation of abnormal liver tests; renal-impairment-specific monitoring is not supported by the provided excerpts for hepatic adverse effects.
Patients taking concomitant medications that affect liver function should be carefully evaluated for tigecycline-induced liver enzyme changes risk.
Partially supported: 5.4 notes multiple concomitant medications in some hepatic dysfunction cases; specific wording about 'carefully evaluated' is not explicitly stated but conceptually aligned.
Healthcare providers should carefully consider the dose and duration of tigecycline treatment, especially in high-risk patients.
Partially supported: 5.4 discusses evaluation/benefit-risk with abnormal LFTs; 2.2 discusses hepatic impairment dosing/caution and monitoring for response.
Prevention and management of tigecycline-induced liver enzyme changes involve regular monitoring of liver function tests and clinical symptoms.
Partially supported: 5.4 recommends monitoring for worsening hepatic function and evaluating risk/benefit; 'regular' and 'clinical symptoms' frequency are not explicitly specified in the provided excerpt.
Discontinuing tigecycline in patients with severe liver enzyme changes or other adverse effects is involved in prevention and management of tigecycline-induced liver enzyme changes.
Partially supported: 5.4 describes monitoring/evaluation and notes hepatic dysfunction may occur after discontinuation; 6.1 documents discontinuation due to adverse reactions.
Common side effects of tigecycline include nausea, vomiting, diarrhea, and liver enzyme changes.
Partially supported: 6.1 lists nausea/vomiting; 5.4 supports hepatic adverse effects; diarrhea is present in 6.1 (diarrhea 12%).
Unsupported Statements
In a study (Journal of Clinical Pharmacology), tigecycline-induced liver enzyme changes were reported in 12.6% of patients receiving tigecycline.
Numeric incidence (12.6%) and journal-study reference are not supported by the provided label excerpts.
Tigecycline-induced liver enzyme changes were often mild and reversible.
No support in provided label excerpts for 'often mild' or 'reversible' characterization.
Older adults may be more susceptible to tigecycline-induced liver enzyme changes.
Provided geriatric section states no overall differences in safety/effectiveness observed; no explicit support for increased susceptibility for hepatic enzyme changes.
Older adults may be more susceptible due to decreased liver function and increased sensitivity to medications.
The provided geriatric excerpt does not provide this mechanistic rationale; no label support in provided sections.
Patients with pre-existing liver disease (e.g., cirrhosis or hepatitis) may be at higher risk for tigecycline-induced liver enzyme changes.
2.2 addresses dosing in hepatic impairment (Child Pugh C caution/monitor), but provided excerpts do not explicitly state 'higher risk for liver enzyme changes' for pre-existing liver disease.
Patients with pre-existing liver disease may be at higher risk due to compromised liver function.
2.2 supports different dosing/caution in severe hepatic impairment but does not explicitly state this causal risk explanation.
Higher doses and longer durations of tigecycline treatment may increase the risk of tigecycline-induced liver enzyme changes.
No dose-duration-to-hepatic-enzyme-risk relationship is stated in the provided label excerpts.
Patients with renal impairment may be at higher risk for tigecycline-induced liver enzyme changes.
No support in provided label excerpts linking renal impairment to hepatic enzyme change risk.
Patients with renal impairment may be at higher risk due to decreased clearance of tigecycline.
No support in provided label excerpts for a clearance-based mechanism relating renal impairment to hepatic enzyme changes.
Regular liver function tests should be performed in high-risk patients to monitor for tigecycline-induced liver enzyme changes.
5.4 supports monitoring/evaluating abnormal tests, but the excerpt does not specify routine testing frequency.
Dose adjustment of tigecycline based on liver function tests and clinical response is involved in prevention and management of tigecycline-induced liver enzyme changes.
The provided label excerpt specifies hepatic impairment dosing (Child Pugh C) but does not state that dosing is adjusted based on LFT trends/response for hepatic adverse effects.
Tigecycline is a broad-spectrum antibiotic that inhibits protein synthesis by binding to the 30S ribosomal subunit.
The provided label excerpts for mechanism are not shown with this specific 30S binding/protein synthesis wording (12.1 excerpt provided only identifies it as a tetracycline-class antibacterial).
Regular liver function tests and clinical symptoms should be monitored in high-risk patients receiving tigecycline for liver enzyme changes.
'Regular' and 'clinical symptoms' monitoring specifics are not explicitly stated in the provided hepatic adverse effects excerpt.
Patients with renal impairment should be carefully evaluated and monitored for liver enzyme changes when receiving tigecycline.
Renal-impairment-specific monitoring for hepatic enzyme changes is not supported by provided excerpts.
Contradictions
High
AI Statement
The recommended dose of tigecycline is 100 mg intravenously every 12 hours for 5-14 days.
Label Reference
2.1 Recommended Adult Dosage: initial dose 100 mg, followed by 50 mg every 12 hours; duration varies by indication (5-14 days for cSSSI/cIAI; 7-14 days for CABP).
Important Omissions
No claims were evaluated regarding boxed warnings and other serious warnings (all-cause mortality; mortality imbalance and lower cure rates in hospital-acquired pneumonia; anaphylaxis; pancreatitis) even though they are central safety sections in the label.
Importance:
Moderate
Safety Assessment
Potential Patient Risk:
High
A major dosing contradiction (100 mg q12h instead of 100 mg initial then 50 mg q12h) could lead to clinically significant under/overexposure; multiple other safety-related statements were unsupported or lacked label-grounded specificity.
Regulatory Assessment
| On Label |
No |
| Off-label Discussion |
No |
| Promotes Unapproved Use |
No |
| Hallucination Risk |
Medium |
Recommendation
Not Aligned
Primary Issue
Recommended adult dosing is contradicted by the FDA label (q12h maintenance dose incorrect and regimen incomplete).
Suggested Improvement
Replace the dosing statement with the labeled regimen: initial 100 mg IV followed by 50 mg IV every 12 hours; infusion over ~30–60 minutes; duration guided by indication (5–14 days for cSSSI/cIAI; 7–14 days for CABP). Remove unsupported claims about numeric incidence, reversibility/specific severity, renal-impairment risk for hepatic enzymes, and routine LFT frequency. Keep hepatic monitoring/evaluation language aligned to 5.4.